← Eichor
Study identifier: NCT05876598 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

BACTERIUM: Study for a Machine-learning-based Model to Predict Bloodstream Infections

Condition: Infection, Bloodstream  ·  Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

PhaseN/A
Planned participants5000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

An increase of healthcare-associated infections caused by multidrug- resistant organisms (MRDO) is currently observed. One of the main causes of the emergence of a MDRO infection is an overuse of antibiotics. Therefore, saving useless antibiotic treatment is currently a priority from a public health point of view. The evaluation of the risk of having a bloodstream infection will allow both activating faster treatment decisions (when the risk is significantly high) or to save useless resources in terms of diagnostic tests and treatments, also limiting the potential for side effects (when the risk is significantly low).

This description comes directly from the study's public registry record.

Talk to the study team

rita murri  ·  003930154945  ·  rita.murri@policlinicogemelli.it

Always discuss trial participation with your own doctor first.

Locations (1)

Fondazione Policlinico Agostino Gemelli IrccsRome, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05876598